The stock of Cognition Therapeutics Inc (CGTX) has gone up by 34.19% for the week, with a 37.61% rise in the past month and a 23.97% rise in the past quarter. The volatility ratio for the week is 37.66%, and the volatility levels for the past 30 days are 16.95% for CGTX. The simple moving average for the past 20 days is 30.16% for CGTX’s stock, with a -50.67% simple moving average for the past 200 days.
Is It Worth Investing in Cognition Therapeutics Inc (NASDAQ: CGTX) Right Now?
The 36-month beta value for CGTX is at 1.07. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CGTX is 35.21M, and currently, shorts hold a 7.62% of that float. The average trading volume for CGTX on December 23, 2024 was 6.68M shares.
CGTX) stock’s latest price update
Cognition Therapeutics Inc (NASDAQ: CGTX)’s stock price has gone decline by -3.95 in comparison to its previous close of 0.63, however, the company has experienced a 34.19% increase in its stock price over the last five trading days. benzinga.com reported 2024-12-18 that Cognition Therapeutics, Inc. CGTX revealed positive results from the exploratory Phase 2 SHIMMER study demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with dementia with Lewy bodies (DLB).
Analysts’ Opinion of CGTX
Many brokerage firms have already submitted their reports for CGTX stocks, with B. Riley Securities repeating the rating for CGTX by listing it as a “Buy.” The predicted price for CGTX in the upcoming period, according to B. Riley Securities is $1.50 based on the research report published on December 19, 2024 of the current year 2024.
Oppenheimer gave a rating of “Outperform” to CGTX, setting the target price at $22 in the report published on November 03rd of the previous year.
CGTX Trading at 25.32% from the 50-Day Moving Average
After a stumble in the market that brought CGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.48% of loss for the given period.
Volatility was left at 16.95%, however, over the last 30 days, the volatility rate increased by 37.66%, as shares surge +44.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +54.06% upper at present.
During the last 5 trading sessions, CGTX rose by +36.74%, which changed the moving average for the period of 200-days by -68.70% in comparison to the 20-day moving average, which settled at $0.4656. In addition, Cognition Therapeutics Inc saw -67.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGTX starting from Ricciardi Lisa, who purchase 5,700 shares at the price of $1.75 back on Mar 14 ’24. After this action, Ricciardi Lisa now owns 291,345 shares of Cognition Therapeutics Inc, valued at $9,975 using the latest closing price.
Stock Fundamentals for CGTX
Current profitability levels for the company are sitting at:
- -157.08 for the present operating margin
- 0.49 for the gross margin
The net margin for Cognition Therapeutics Inc stands at -92.12. The total capital return value is set at -3.93. Equity return is now at value -157.90, with -103.30 for asset returns.
Based on Cognition Therapeutics Inc (CGTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -135.89. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -2014.9.
Currently, EBITDA for the company is -25.51 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of 11.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.
Conclusion
In conclusion, Cognition Therapeutics Inc (CGTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
